1. Sono-Controllable and ROS-Sensitive CRISPR-Cas9 Genome Editing for Augmented/Synergistic Ultrasound Tumor Nanotherapy
- Author
-
Yu Chen, Huijing Xiang, Wencheng Wu, Dou Du, Caihong Dong, Haohao Yin, Bangguo Zhou, Hui-Xiong Xu, and Yinying Pu
- Subjects
Materials science ,Porphyrins ,Cell Survival ,Polymers ,Ultrasonic Therapy ,Transplantation, Heterologous ,Mice, Nude ,Antineoplastic Agents ,Cleavage (embryo) ,Mice ,Genome editing ,In vivo ,Cell Line, Tumor ,Neoplasms ,CRISPR ,Animals ,Humans ,General Materials Science ,Metal-Organic Frameworks ,chemistry.chemical_classification ,Gene Editing ,Reactive oxygen species ,Cas9 ,Mechanical Engineering ,Sonodynamic therapy ,Phosphoric Monoester Hydrolases ,Cell biology ,DNA Repair Enzymes ,chemistry ,Mechanics of Materials ,Apoptosis ,Nanoparticles ,CRISPR-Cas Systems ,Reactive Oxygen Species ,RNA, Guide, Kinetoplastida - Abstract
The potential of the cluster regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (Cas9)-based therapeutic genome editing is severely hampered by the difficulties in precise regulation of the in vivo activity of the CRISPR-Cas9 system. Herein, sono-controllable and reactive oxygen species (ROS)-sensitive sonosensitizer-integrated metal-organic frameworks (MOFs), denoted as P/M@CasMTH1, are developed for augmented sonodynamic therapy (SDT) efficacy using the genome-editing technology. P/M@CasMTH1 nanoparticles comprise singlet oxygen (1 O2 )-generating MOF structures anchored with CRISPR-Cas9 systems via 1 O2 -cleavable linkers, which serve not only as a delivery vector of CRISPR-Cas9 targeting MTH1, but also as a sonoregulator to spatiotemporally activate the genome editing. P/M@CasMTH1 escapes from the lysosomes, harvests the ultrasound (US) energy and converts it into abundant 1 O2 to induce SDT. The generated ROS subsequently trigger cleavage of ROS-responsive thioether bonds, thus inducing controllable release of the CRISPR-Cas9 system and initiation of genome editing. The genomic disruption of MTH1 conspicuously augments the therapeutic efficacy of SDT by destroying the self-defense system in tumor cells, thereby causing cellular apoptosis and tumor suppression. This therapeutic strategy for synergistic MTH1 disruption and abundant 1 O2 generation provides a paradigm for augmenting SDT efficacy based on the emerging nanomedicine-enabled genome-editing technology.
- Published
- 2021